Cardiovascular drug prescriptions and risk of depression in diabetic patients

Journal of Clinical Epidemiology

Volumn 52, Issue 11, 1999, Pages 1103-1109

  Rathmann, Wolfgang ^a   Haastert, Burkhard ^a   Roseman, Jeffrey M ^b   Giani, Guido ^a  

^a LEIBNIZ CENTER FOR DIABETES RESEARCH AT HEINRICH HEINE UNIVERSITY DÜSSELDORF   (Germany)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Beta blocker; Calcium channel blocker; Cardiovascular drugs; Depression; Diabetes mellitus; Drug prescription

Indexed keywords

ANTIDEPRESSANT AGENT; ANTIDIABETIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARDIOVASCULAR AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ADULT; AGED; ARTICLE; CASE CONTROL STUDY; COMORBIDITY; CONTROLLED STUDY; DEPRESSION; DIABETES MELLITUS; FEMALE; GERMANY; HEART DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; PRIORITY JOURNAL; RISK;

ADRENERGIC BETA-ANTAGONISTS; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; DEPRESSION; DIABETES COMPLICATIONS; DRUG THERAPY, COMBINATION; FEMALE; GERMANY; HUMANS; MALE; ODDS RATIO; PRESCRIPTIONS, DRUG; PREVALENCE; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 0032885944     PISSN: 08954356     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0895-4356(99)00082-7     Document Type: Article

References (25)

1. Avorn J., Everitt D.E., Weiss S. Increased antidepressant use in patients prescribed β-blockers. JAMA. 255:1986;357-360.
2. Thiessen B.Q., Wallace S.M., Blackburn J.L., Wilson T.W., Bergman U. Increased prescribing of antidepressants subsequent to β-blocker therapy. Arch Intern Med. 150:1990;2286-2290.
3. Prisant L.M., Spruill W.J., Fincham J.E., Wade W.E., Carr A.A., Adams M.A. Depression associated with antihypertensive drugs. J Fam Pract. 33:1991;481-485.
4. Bright R.A., Everitt D.E. β-blockers and depression. Evidence against an association JAMA. 267:1992;1783-1787.
5. Gerstman B.B., Jolson H.M., Bauer M., Cho P., Livingston J.M., Platt R. The incidence of depression in new users of beta-blockers and selected antihypertensives. J Clin Epidemiol. 49:1996;809-815.
6. Hallas J. Evidence of depression provoked by cardiovascular medication. A prescription sequence symmetry analysis Epidemiology. 7:1996;478-484.
7. Biriell C., McEwen J., Sanz E. Depression associated with diltiazem. BMJ. 299:1989;796.
8. Lindberg G., Bingefors K., Ranstam J., Rastam L., Melander A. Use of calcium channel blockers and risk of suicide. Ecological findings confirmed in population based cohort study BMJ. 316:1998;741-745.
9. Pahor M., Guralnik J.M., Ferrucci L., Corti M.C., Salive M.E., Cerhan J.R.et al. Calcium-channel blockade and incidence of cancer in aged populations. Lancet. 348:1996;493-497.
10. Jick H., Jick S., Derby L.E., Vasilakis C., Myers M.W., Meier C.R. Calcium-channel blockers and risk of cancer. Lancet. 349:1997;525-528.
11. Michels K.B., Rosner B.A., Walker A.M., Stampfer M.J., Manson J.E., Colditz G.A.et al. Calcium channel blockers, cancer incidence, and cancer mortality in a cohort of U.S. women. The nurses' health study Cancer. 83:1998;2003-2007.
12. Rosenberg L., Rao R.S., Palmer J.R., Strom B.L., Stolley P.D., Zauber A.G.et al. Calcium channel blockers and the risk of cancer. JAMA. 279:1998;1000-1004.
13. Aldermann M.H., Cohen H., Roque R., Madhavan S. Effect of long-acting and short-acting calcium antagonists on cardiovascular outcomes in hypertensive patients. Lancet. 349:1997;594-598.
14. Rathmann W., Haastert B., Roseman J.M., Gries F.A., Giani G. Prescription drug use and costs among diabetic patients in primary health care practices in Germany. Diabetes Care. 21:1998;389-397.
15. Lustman P.J., Gavard J.A. Psychosocial aspects of diabetes in adult populations. National Diabetes Data Group, Eds Diabetes in America. 1995;National Institutes of Health, Bethesda. NIH Publ. No. 95-1468.
16. Rathmann W., Haastert B., Delling B., Gries F.A., Giani G. Postmarketing surveillance of adverse drug reactions. A correlational study approach using multiple data sources Pharmacoepidemiol Drug Safety. 7:1998;51-57.
17. Kendall M.J. Clinical relevance of pharmacokinetic differences between beta blockers. Am J Cardiol. 80:1997;15J-19J.
18. Drayer D.E. Lipophilicity, hydrophilicity, and the central nervous system side effects of beta blockers. Pharmacotherapy. 7:1987;87-91.
19. Gengo F.M., Huntoon L., McHugh W.B. Lipid-soluble and water-soluble beta-blockers. Comparison of the central nervous system depressant effect. Arch Intern Med. 147:1987;39-43.
20. Van Marwijk H.W., de Bock G.H., Hermans J., Mulder J.D., Springer M.P. Prevalence of depression and clues to focus diagnosis. A study among Dutch general practice patients 65+ years of age Scand J Prim Health Care. 14:1996;142-147.
21. Nielsen A.C., Williams T.A. Depression in ambulatory medical patients. Prevalence by self-reported questionnaire and recognition by non-psychiatric physicians Arch Gen Psychiatry. 37:1980;999-1004.
22. Wingard D.L., Barrett-Connor E. Heart disease and diabetes. National Diabetes Data Group, Eds Diabetes in America. 1995;National Institutes of Health, Bethesda. NIH Publ. No. 95-1468.
23. Standl E., Stiegler H., Roth R., Schulz K., Lehmacher W. On the impact of hypertension on the prognosis of NIDDM. Results of the Schwabing GP-program Diabete Metab. 15:1989;352-358.
24. Bundesverband der Pharmazeutischen Industrie Eds Rote Liste 1996. 1996;Editio Cantor, Aulendorf.
25. Jick H., Rodriguez L.A.G., Perez-Gutthann S. Principles of epidemiological research on adverse and beneficial drug effects. Lancet. 352:1998;1767-1770.